http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Viatris Inc (VTRS) Launches Unmind
-
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
-
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
-
Viatris Inc (VTRS) Appoints Corinne Le Goff as Chief Commercial Officer
-
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
-
Viatris Inc (VTRS) Announces Launch of RYZUMVl in the US
-
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States
-
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
-
Idorsia and Viatris successfully close the transaction for the global research and development collaboration
-
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
-
Viatris Inc (VTRS) and Idorsia Enter Global Research and Development Collaboration
-
Idorsia and Viatris enter into a significant global research and development collaboration
-
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
-
Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results
-
Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference
-
Viatris Inc (VTRS) Appoints Doretta Mistras as CFO, Philippe Martin as Chief R&D Officer
-
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Phil
-
Viatris (VTRS) Shareholders Re-elect All Nominated Directors and Approve All Voting Matters
-
Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders
-
Viatris Partners With Comfort Cases to Support Youth in U.S. Foster Care
-
Viatris to Participate in the Jefferies London Healthcare Conference
-
Viatris Inc (VTRS) and Theravance Biopharma (TBPH) Announce Positive Top-Line Results from YUPELRI Phase III Trial in China
-
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
-
Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]
-
Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance
-
Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row
-
Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row
-
Rajiv Malik to Retire as President of Viatris Effective April 1, 2024
-
Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking
-
Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023
-
Viatris Inc (VTRS) Announces Agreements on Remaining Planned Divestitures
-
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
-
Viatris Inc (VTRS) and Ocuphire Pharma (OCUP) Announce FDA Approval of RYZUMVl
-
Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agoni
-
Viatris Named to TIME's World’s Best Companies 2023 List
-
Viatris Named to TIME's World’s Best Companies 2023 List
-
Viatris Named to TIME's World’s Best Companies 2023 List
-
Viatris Named to TIME's World's Best Companies 2023 List
-
Viatris Inc (VTRS) Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir/Dolutegravir/Lamivudine
-
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
-
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
-
Viatris Inc (VTRS) nd Mapi Pharma Announce FDA Acceptance of NDA Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
-
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
-
Viatris Inc (VTRS) Announces Launch of Breyna Inhalation Aerosol
-
Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstru
-
Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023
-
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – VTRS
-
ROSEN, A LEADING AND RANKED FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – VTRS
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – VTRS
-
Viatris Named to USA Today’s Inaugural List of America’s Climate Leaders 2023
